Natrecor for Pulmonary Hypertension in Lung Transplants

Phase 4CompletedNCT00205426

University of Wisconsin, Madison7 enrolled

Overview

This study seeks to demonstrate that Natrecor® (nesiritide) is safe and effective and has a favorable hemodynamic profile in lung transplant recipients that will allow for the avoidance of inhaled nitric oxide (iNO) use. It is estimated that the use of nesiritide will decrease the otherwise historically mandated use of iNO by 50%, as compared to the necessity of iNO use by matched historical controls.

A condition called ischemic reperfusion injury (IRI) occurs in all lung transplants. The amount of reperfusion injury varies from person to person. IRI occurs when the blood supply to tissue (in this case, transplanted lung(s)) is decreased and then is restored. IRI can cause a decrease in function in a newly transplanted lung. When this occurs, or when people have pulmonary hypertension (high blood pressure in your lungs), doctors use Nitric Oxide to improve the pressure and blood supply to the transplanted lung. Nitric Oxide (NO) is given by inhalation while patients are on a ventilator (breathing machine). Because NO must be given by a ventilator and because patients on ventilators must be in an intensive care unit, the cost of treating people with NO is very high. NO can also cause rebound pulmonary hypertension (high blood pressure in the lungs that reoccurs) when it is stopped. Because of these reasons, doctors are looking for other treatments for IRI and pulmonary hypertension. A drug called Natrecor has been shown to reduce pulmonary pressures in heart transplant patients. Doctors believe it may be helpful to lung transplant patients as well.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Pulmonary Hypertension

Interventions

NatrecorDRUG

Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Single or double lung transplant or heart/lung transplant recipient * Planned use of Natrecor * Pulmonary artery (PA) systolic pressures \> 35 Exclusion Criteria: * Previous lung transplant * Use of Prolastin after pneumonectomy * Mean arterial pressure of \< 55 * Known allergy or sensitivity to nesiritide * Females of childbearing potential with a positive pregnancy test or women who are breast feeding * Use of nesiritide, for any reason, within 30 days prior to transplant

Locations (1)

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

To evaluate the safety and efficacy of Natrecor® in reducing nitric oxide used perioperatively in patients undergoing single or double lung transplantation who have or are at risk for developing pulmonary hypertension

Secondary Outcomes

To compare total cost-effective evaluation between patients receiving Natrecor and those who received iNO

To compare length of stay in the Intensive Care Unit (ICU)

To compare renal function as defined by peak serum creatinine and calculated creatinine clearance during the first 72 hours post-transplant

To compare necessity of CPB between Natrecor® versus nitric oxide

To compare hemodynamic parameters

To compare length of stay (total)

To compare time to dry weight

To compare duration of mechanical ventilation

To compare pulmonary parameters

To compare IRI via chest x-ray and PAO2/FIO2 ratio

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.